secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001725160-24-000012
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Diana Hausman as CMO, Kyle Rasbach as CBO; receives Nasdaq notice on audit committee
--------------------------------------------------------------------------------

- Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.
- Kyle Rasbach appointed CBO; formerly portfolio manager at Eventide Asset Management.
- Dr. Hausman resigned from Board and Audit Committee, causing Nasdaq audit committee independence non-compliance.
- Company has 180 days (by July 17, 2024) to appoint a third independent director to regain compliance.
- Dr. Brownstein receives severance: 10 months base salary + 2023 & prorated 2024 target bonuses, 12 months COBRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/zntl-20240119.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer